FDA/CDC

Moderna COVID-19 vaccine wins decisive recommendation from FDA panel


 

mRNA vaccines in the lead

An FDA emergency clearance for Moderna’s product would be another vote of confidence in a new approach to making vaccines. Both the Pfizer-BioNTech and Moderna vaccines provide the immune system with a kind of blueprint in the form of genetic material, mRNA. The mRNA sets the stage for the synthesis of the signature spike protein that the SARS-CoV-2 virus uses to attach to and infect human cells.

In a December 15 commentary for this news organization Michael E. Pichichero, MD, wrote that the “revolutionary aspect of mRNA vaccines is the speed at which they can be designed and produced.”

“This is why they lead the pack among the SARS-CoV-2 vaccine candidates and why the National Institute of Allergy and Infectious Diseases provided financial, technical, and/or clinical support. Indeed, once the amino acid sequence of a protein can be determined (a relatively easy task these days) it’s straightforward to synthesize mRNA in the lab — and it can be done incredibly fast,” he wrote.

The FDA allowed one waiver for panelist James K. Hildreth in connection with his personal relationship to a trial participant and his university’s participation in vaccine testing.


This article first appeared on Medscape.com.

Pages

Recommended Reading

FDA panel overwhelmingly backs emergency authorization for Pfizer COVID vaccine
MDedge Neurology
Just under three million will get COVID-19 vaccine in first week
MDedge Neurology
Vitamin D deficiency in COVID-19 quadrupled death rate
MDedge Neurology
COVID-19 vaccines: Preparing for patient questions
MDedge Neurology
CDC panel recommends Pfizer’s COVID-19 vaccine for people 16 and over
MDedge Neurology
COVID-19 neurologic fallout not limited to the severely ill
MDedge Neurology
Understanding messenger RNA and other SARS-CoV-2 vaccines
MDedge Neurology
COVID-related harm to HCWs must be tracked more rigorously: NAS panel
MDedge Neurology
COVID-19 vaccines: Safe for immunocompromised patients?
MDedge Neurology
Vaccine rollout on track, expect 300 million doses through March: Feds
MDedge Neurology